Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 68
This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Integrin Beta 3 - Pipeline Review, H2 2018'; Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (?3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

The report 'Integrin Beta 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 11 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal and Infectious Disease which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Melanoma, Wounds, Arterial Thrombosis, Cardiovascular Disease, Diabetic Macular Edema, Diabetic Retinopathy, Ischemic Cerebral Stroke, Ischemic Stroke, Lung Cancer, Malabsorption Syndrome, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Pancreatic Cancer, Retinal Vein Occlusion, Sepsis and Venous Leg Ulcers (Crural ulcer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development
Celltrion Inc
Factor Therapeutics Ltd
Merck & Co Inc
SciFluor Life Sciences LLC
Vascular Pharmaceuticals Inc
VDDI Pharmaceuticals
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles
A-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-16Y - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cilengitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonise ITGA5 and ITGB3 for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-0429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSP-68 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OCU-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proagio - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RUC-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetraiodothyroacetic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-2690B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xemilofiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion
Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update
May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase
Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial
Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration
Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial
Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites
Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
May 22, 2017: Factor Therapeutics Appoints Dr. Rosalind Wilson as CEO
May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200
Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update
Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Celltrion Inc, H2 2018
Pipeline by Factor Therapeutics Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by SciFluor Life Sciences LLC, H2 2018
Pipeline by Vascular Pharmaceuticals Inc, H2 2018
Pipeline by VDDI Pharmaceuticals, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Plasminogen Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Jul-2018        Price: US 3480 Onwards        Pages: 132
    Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Plasminogen Market 2018, Forecast to 2023
    Published: 20-Jul-2018        Price: US 4880 Onwards        Pages: 132
    Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). ......
  • Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global Chronic Inflammatory Demyelinating Polyneuropathy Drug market status and forecast, categorizes the global Chronic Inflammatory Demyelinating Polyneuropathy Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Chronic Inflammatory Demye......
  • Global Cluster Headache Syndrome Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 118
    This report studies the global Cluster Headache Syndrome Drug market status and forecast, categorizes the global Cluster Headache Syndrome Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Cluster Headache Syndrome Drug market is valued at million US$ in 2017 and......
  • Global Hodgkin Lymphoma Treatment Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 118
    This report studies the global Hodgkin Lymphoma Treatment market status and forecast, categorizes the global Hodgkin Lymphoma Treatment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Hodgkin Lymphoma Treatment market is valued at million US$ in 2017 and will reach ......
  • Global Medical Morphine Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global Medical Morphine market status and forecast, categorizes the global Medical Morphine market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). Morphine is a pain medication of the opiate variety which is found naturally in a number of plants and animals. I......
  • Global MMR Vaccines Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global MMR Vaccines market status and forecast, categorizes the global MMR Vaccines market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The MMR vaccine (also known as the MPR vaccine after the Latin names of the diseases) is an immunization vaccine against ......
  • Global Herpes Zoste Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 117
    This report studies the global Herpes Zoste Drug market status and forecast, categorizes the global Herpes Zoste Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Herpes Zoste Drug market is valued at million US$ in 2017 and will reach million US$ by the end of 2......
  • Global Crigler-Najjar Syndrome Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 109
    This report studies the global Crigler-Najjar Syndrome Drug market status and forecast, categorizes the global Crigler-Najjar Syndrome Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Crigler-Najjar Syndrome Drug market is valued at million US$ in 2017 and will ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs